Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification

摘要: A decade ago, lung cancer could conveniently be classified into two broad categories—either the small cell carcinoma (SCLC), or non-small (NSCLC), mainly to assist in further treatment related decision making. However, understanding regarding eligibility of adenocarcinoma histology for treatments with agents such as pemetrexed and bevacizumab made it a necessity NSCLC more specific sub-groups. Then, availability molecular targeted therapy oral tyrosine kinase inhibitors (TKIs) gefitinib erlotinib not only emphasized need accurate sub-classification cancer, but also heralded important role profiling adenocarcinomas. Given remarkable advances biology, oncology radiology, felt revised classification adenocarcinoma, since existing World Health Organization (WHO) published year 2004 was pathological system classification. Thus, there combined effort by International Association Study Lung Cancer (IASLC), American Thoracic Society (ATS) European Respiratory (ERS) an inculcate newly established perspectives from clinical, radiological aspects evolving modern This review provides summary recent biology respect adenocarcinoma. Also, brief summation salient recommendations provided IASLC/ATS/ERS adenocarcinomas is provided. Lastly, discussion future prospects included.